Anest. intenziv. Med. 2000;11(1):31-36

Early HFO Application Decreases Mortality of Pediatric Acute Respiratory Distress SyndromeArticles

M. Fedora, M. Klimovič, M. Šeda, P. Dominik, R. Nekvasil
ARO a ECMO centrum Fakultní dětské nemocnice Brno, přednosta ARO prim. MUDr. Michal Klimovič, vedoucí ECMO centra doc. MUDr. Roman Nekvasil

Objective:
To evaluate the effect of the duration of conventional mechanical ventilation prior to high-frequency oscillation on the effectivity of HFOand patient survival.Study design: Retrospective analysis of the set of patients.Setting: Department of Anesthesiology and Intensive Care; ECMO Center University Children's Hospital Brno.Patients: 26 patients > 1 month of age with severe hypoxemic respiratory failure and ARDS. Mean age was 44.4 months (three adult patients - 17,19 and 24 years), mean weight 13.8 kilograms, maximum weight 70 kilograms, 17 boys, 9 girls. 15 patients died. 84,6% per cent of patients sufferedfrom basic medical disease, mean admission PRISM score was 22. Nine patients met ECMO criter ia. In two of them ECMO was not necessary, in 5ECMO was contraindicated, two patients were treated with ECMO. Four patients ventilated in H FO mode were also treated with NO, in two of thempartial liquid ventilation was also implemented.

Methods: Patients were ventilated in PCV or PRVC modes with limited peak inspiratory pressures and permissive hypercapnia. Tracheal gasinsufflation was instituted if paCO2 > 10.0 kPa and/or pH < 7.20. HFO was started if there was a need for FiO2 > 0,6 and Paw > 15 cmH2O to maintainperipheral blood saturation > 90% or due to persistent hypercapnia and/or acidosis with C MV with TGI. HFO was designed as "High Volume Strategy"to recruit the alveoli and keep the optimal lung volume. Before switching back to CMV, following criteria had to be met: Paw 15-20 cmH2O, FiO2 90%, FiO2 < 0.4 Paw < 15 cmH2O, normal pH with respiratory rate (RR) < 30/min and PIP < 35 cmH2O. Patientswere divided into two groups with respect to the duration of CMV prior to HFO: early application (CMV pre-HFO Ł 24 hours; 17 patients) and theapplication (CMV pre-HFO > 24 hours; 9 patients). Following data were collected for each group separately: demographic data (gender, age, weight,admission PRISM score), duration of ventilation (CMV prior to HFO, HFO, CMV after HFO and total duration of ventilation), acid-base status (pH,paO2, paCO2) and indexes - AaDO2, oxygenation index and hypoxemia score (paO2/FiO2).

Results: Severity of respiratory failure was comparable in both groups (paO2/FiO2 76.9 vs 75.9 mmHg; OI 31.2 vs. 36; AaDO2 56.3 vs 55 kPa).There are no statistically significant differences in the followed parameters during the observational period. There were no differences in mean age,weight, PRISM score, duration of HFO, duration of CMV after HFO and total duration of mechanical ventilation. We found a statistically significantdifferences in mortality - in the group with early application 58.8% of patients survived, in spite of 12.5% in the group with late application of HFO.Overall survival rate was 42 per cent (11/26 patients).

Conclusion: The duration of mechanical ventilation prior to HFO possess a significant ef fect upon the effectivity of HFO and patient survival. IfHFO is implemented early (CMV prior to HFO Ł 24 hours), survival rate is much higher compared to late implementation of HFO (CMV prior toHFO > 24 hours) - 58.8% and 12.5%, respectively.

Keywords: high frequency oscillation (HFO); early application; late application; respiratory failure; mortality; children

Published: February 1, 2000  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fedora M, Klimovič M, Šeda M, Dominik P, Nekvasil R. Early HFO Application Decreases Mortality of Pediatric Acute Respiratory Distress Syndrome. Anest. intenziv. Med. 2000;11(1):31-36.
Download citation




Anesteziologie a intenzivní medicína

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.